195 related articles for article (PubMed ID: 30965052)
1. Total and out-of-pocket costs of different primary management strategies in ovarian cancer.
Suidan RS; He W; Sun CC; Zhao H; Rauh-Hain JA; Fleming ND; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Aug; 221(2):136.e1-136.e9. PubMed ID: 30965052
[TBL] [Abstract][Full Text] [Related]
2. Cost of Care for the Initial Management of Ovarian Cancer.
Bercow AS; Chen L; Chatterjee S; Tergas AI; Hou JY; Burke WM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Obstet Gynecol; 2017 Dec; 130(6):1269-1275. PubMed ID: 29112648
[TBL] [Abstract][Full Text] [Related]
3. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
5. Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study.
Giordano SH; Niu J; Chavez-MacGregor M; Zhao H; Zorzi D; Shih YT; Smith BD; Shen C
Cancer; 2016 Nov; 122(22):3447-3455. PubMed ID: 27723214
[TBL] [Abstract][Full Text] [Related]
6. How Have Patient Out-of-pocket Costs for Common Outpatient Orthopaedic Foot and Ankle Surgical Procedures Changed Over Time? A Retrospective Study From 2010 to 2020.
Goldfarb SI; Xu AL; Gupta A; Mun F; Durand WM; Gonzalez TA; Aiyer AA
Clin Orthop Relat Res; 2024 Feb; 482(2):313-322. PubMed ID: 37498201
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of Physician Estimates of Out-of-Pocket Costs for Medication Filling.
Sloan CE; Millo L; Gutterman S; Ubel PA
JAMA Netw Open; 2021 Nov; 4(11):e2133188. PubMed ID: 34739059
[TBL] [Abstract][Full Text] [Related]
8. Out-of-Pocket Costs Among Patients With a New Cancer Diagnosis Enrolled in High-Deductible Health Plans vs Traditional Insurance.
Fu SJ; Rose L; Dawes AJ; Knowlton LM; Ruddy KJ; Morris AM
JAMA Netw Open; 2021 Dec; 4(12):e2134282. PubMed ID: 34935922
[TBL] [Abstract][Full Text] [Related]
9. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
10. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
Behbakht K; Cohn DE; Straughn JM
Gynecol Oncol; 2018 Oct; 151(1):4-5. PubMed ID: 30068488
[No Abstract] [Full Text] [Related]
12. Cost of care for the initial management of cervical cancer in women with commercial insurance.
Blanco M; Chen L; Melamed A; Tergas AI; Khoury-Collado F; Hou JY; St Clair CM; Ananth CV; Neugut AI; Hershman DL; Wright JD
Am J Obstet Gynecol; 2021 Mar; 224(3):286.e1-286.e11. PubMed ID: 32818476
[TBL] [Abstract][Full Text] [Related]
13. Out-of-Pocket Spending for Non-Birth-Related Hospitalizations of Privately Insured US Children, 2017 to 2019.
Carlton EF; Becker NV; Moniz MH; Scott JW; Prescott HC; Chua KP
JAMA Pediatr; 2023 May; 177(5):516-525. PubMed ID: 36972040
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
[TBL] [Abstract][Full Text] [Related]
15. Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm.
Cole AL; Barber EL; Gogate A; Tran AQ; Wheeler SB
Int J Gynecol Cancer; 2018 Jul; 28(6):1077-1084. PubMed ID: 29683880
[TBL] [Abstract][Full Text] [Related]
16. The Economic Burden of Out-of-Pocket Expenses for Plastic Surgery Procedures.
Billig JI; Chen JS; Lu YT; Chung KC; Sears ED
Plast Reconstr Surg; 2020 Jun; 145(6):1541-1551. PubMed ID: 32459783
[TBL] [Abstract][Full Text] [Related]
17. Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
Leopold C; Wagner AK; Zhang F; Lu CY; Earle CC; Nekhlyudov L; Ross-Degnan D; Wharam JF
Breast Cancer Res Treat; 2018 Sep; 171(2):449-459. PubMed ID: 29855813
[TBL] [Abstract][Full Text] [Related]
18. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
Jazowski SA; Wilson L; Dusetzina SB; Zafar SY; Zullig LL
JAMA Netw Open; 2022 Jun; 5(6):e2215720. PubMed ID: 35671056
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy vs primary debulking surgery for advanced ovarian cancer. What is the debate regarding the ideal treatment: approach? age? or cost?
Salani R
Am J Obstet Gynecol; 2015 Jun; 212(6):695-6. PubMed ID: 26042956
[No Abstract] [Full Text] [Related]
[Next] [New Search]
